Rapidly Progressive Dementia in a Man With HIV Infection and Undetectable Plasma Viral Load
Neurol 100:344-348, Chishimba,L.C.,et al, 2023
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Central Nervous System Involvement in Erdheim-Chester Disease
Neurol 95:e2746-e2754, Aubart,F.C.,et al, 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Acute Disseminated Encephalomyelitis in 228 Patients
Neurol 86:2085-2096, Koelman, D.L.H.,et al, 2016
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
DARS-Associated Leukoencephalopathy can Mimic a Steroid-Responsive Neuroinflammatory Disorder
Neurol 84:226-230,218, Wolf, N.I.,et al, 2015
Progressive Multifocal Leukoencephalopathy in Patients with Sarcoidosis
Neurol 82:1307-1313, Jamilloux, Y.,et al, 2014
A Young Woman with Rapid Mental Deterioration and Leukoencephalopathy
Neurol 83:e182-e186, Biotti, D.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Opiates and Synthetic Analgesic Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1201, Ropper, A.H.,et al, 2014
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Progressive Multifocal Leukoencephalopathy
Adams & Victors Principles of Neurology, Chp 33, pg 767, Ropper, A.H.,et al, 2014
Misdiagnosis of Treatable Stroke Mimic: The Case for HIV Screening in Practice Guidelines
Neurohosp 3:125-130, Finelli, P.F., 2013
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
The Autosomal Recessive Cerebellar Ataxias
NEJM 366:636-646, Anheim,M.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Ann Neurol 70:305-322, Mateen, F.J.,et al, 2011
Progressive Multifocal Leukoencephalopathy: Prognosis and treatment
UpToDate, June, Koralnik, I.J.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Clinicopath Conf, Inflamatory Cerebral Amyloid Angiopathy,
NEJM 363:373-381, Case 22-2010, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Vitamin B12-Responsive Severe Leukoencephalopathy and Autonomic Dysfunction in a Patient With "Normal" Serum B12 Levels
JNNP 81:1369-1371, Graber,J.J.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Leukodystrophies: Classification, Diagnosis, and Treatment
Neurologist 15:319-328, Costello,D.,et al, 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Overview of Phenylketonuria
UptoDate (May), Bodamer,O.A., 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Characteristics and Antecedents of Progressive Multifocal Leukoencephalopathy in an Insured Population
Neurol 67:884-886, Eng,P.M.,et al, 2006
Immune Reconstitution Inflammatory Syndrome Associated with PML in AIDS: A Treatable Disorder
Neurol 67:1692-1694, Martinez,J.V.,et al, 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Sustained Recovery of Progressive Multifocal Leukoencephalopathy After Treatment with IL-2
Neurol 65:1510, Kunschner,L. &Scott,T.F., 2005
Update on Primary Central Nervous System Lymphoma
Curr Opin Neurol 18:645-653, Plotkin,S.R., 2005
Hemicraniectomy as a Successful Treatment of Mass Effect in Acute Disseminated Encephalomyelitis
Neurol 61:420-421, von Stuckrad-Barre,S.,et al, 2003
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002